Genome-wide association studies (GWAS) have successfully identified numerous genetic variants associated with diverse complex phenotypes and diseases, and provided tremendous opportunities for further analyses using summary association statistics. Recently, Pickrell et al. developed a robust method for causal inference using independent putative causal SNPs. However, this method may fail to infer the causal relationship between two phenotypes when only a limited number of independent putative causal SNPs identified. Here, we extended Pickrell's method to make it more applicable for the general situations. We extended the causal inference method by replacing the putative causal SNPs with the lead SNPs (the set of the most significant SNPs in each independent locus) and tested the performance of our extended method using both simulation and empirical data. Simulations suggested that when the same number of genetic variants is used, our extended method had similar distribution of test statistic under the null model as well as comparable power under the causal model compared with the original method by Pickrell et al. But in practice, our extended method would generally be more powerful because the number of independent lead SNPs was often larger than the number of independent putative causal SNPs. And including more SNPs, on the other hand, would not cause more false positives. By applying our extended method to summary statistics from GWAS for blood metabolites and femoral neck bone mineral density (FN-BMD), we successfully identified ten blood metabolites that may causally influence FN-BMD. We extended a causal inference method for inferring putative causal relationship between two phenotypes using summary statistics from GWAS, and identified a number of potential causal metabolites for FN-BMD, which may provide novel insights into the pathophysiological mechanisms underlying osteoporosis.
Introduction
Inferring the causal direction between correlated phenotypes is a pervasive issue in biology that simple regression and association analysis cannot answer. Randomized controlled trial is a scientific method which randomly allocated the study participants to one or another treatment (Chalmers et al. 1981) , and is widely taken as the gold standard for establishing causal inference (Cartwright 2009 ). In the era of genome-wide association studies (GWAS) and high-throughput genomic technologies, genetic data are routinely available on large well-phenotyped studies (Davey Smith and Hemani 2014) . Mendelian randomization uses genetic variants as instrumental variables to estimate and test for the causal effect of an exposure variable on an outcome (Ference et al. 2012 ). Mendelian randomization is widely used to investigate the causal relationship between two phenotypes (Burgess et al. 2016; Dalbeth et al. 2015) . However, Mendelian randomization requires the strong assumption that the variant does Xiang-He Meng and Hui Shen contributed equally to this work.
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The online version of this article (https ://doi.org/10.1007/s0043 9-018-1876-1) contains supplementary material, which is available to authorized users. not influence the two phenotypes via independent mechanisms (Ziegler et al. 2015) . Genetic correlation, which is the proportion of variance of two phenotypes shared, is useful to provide etiological insights and estimate the degree of pleiotropy or causal overlap (Bulik-Sullivan et al. 2015) . Pickrell et al. (Pickrell et al. 2016 ) recently developed a robust method to infer evidence of causal relationship between two phenotypes using independent putative causal SNPs inferred from GWAS summary data. This method was similar like a bi-directional Mendelian randomization which is useful to distinguish between an exposure causing an outcome and an outcome causing a phenotype (Vimaleswaran et al. 2013; Welsh et al. 2010 ). Pickrell's method infers the causal relationship between the two phenotypes by distinguishing ρ XY (the correlation between effect sizes of putative causal SNPs of phenotype X on phenotype X and phenotype Y) and ρ YX (the correlation between effect sizes of putative causal SNPs of phenotype Y on phenotype Y and phenotype X). However, this method may fail to give causal reference when there were only a limited few independent putative causal SNPs . In Mendelian randomization studies, researchers used the uncorrelated lead SNPs to investigate whether the exposure has a causal effect on the outcome (Mokry et al. 2015; Zhu et al. 2016) . Inspired by this, we extended Pickrell's causal inference method using the independent lead SNPs (the set of the most significant SNPs in each independent locus) to replace the set of putative causal SNPs. Our extended method will be shown here to have comparable or better performance with the Pickrell's method .
Early studies suggested that metabolites may act as intermediary playing important roles in the development of phenotype variation, and genetic variants generally explained a greater proportion of phenotype variance for metabolites than what is generally observed for complex phenotypes (Kettunen et al. 2012 ). This larger contribution of genetic variants will lead to an increased power for detecting the causal relationship between metabolites and complex phenotypes using genetic variants as instrumental variables (Brion et al. 2013; Freeman et al. 2013 ).
Here, we applied our extended method to infer the putative causal relationships between metabolites in blood and femoral neck bone mineral density (FN-BMD). Low FN-BMD is a major risk factor for osteoporosis, an increasingly serious public health problem worldwide (Cummings and Melton 2002; Harvey et al. 2010) . Numerous metabolites have been found to be associated with bone metabolism (Lv et al. 2016) ; however, the causal relationship for many of these metabolites and BMD was not clear and will be assessed here using our extended method. Pickrell et al. (Pickrell et al. 2016 ) developed a robust method to infer whether there was a causal relationship between two phenotypes. The principle is as follows : assuming phenotype X is one of a large number of factors that causally influence phenotype Y, then all the significant variants associated with phenotype X should also have an effect on phenotype Y, and importantly, the effect sizes of these variants on X and Y should be correlated. For example, if one variant has a large effect on phenotype X, then the effect size of this variant on phenotype Y is also expected to be relatively large. On the other hand, the reverse may not be true, that is, for variants that influence phenotype Y, the effect size of these variants on X and Y are not expected to be correlated, since these variants may influence Y through many other mechanisms other than through phenotype X.
Materials and methods

Causal inference
As defined by Pickrell et al., we assumed that there were N X independent genetic variants significantly associated with phenotype X, and N Y independent genetic variants associated with phenotype Y identified from GWAS. β XX was defined as the vector of effect sizes on phenotype X for the N X variants ascertained through the association study of X. β XY was the vector of the N X variants' effect sizes on phenotype Y. Similarly, β YY was defined as the vector of effect sizes on phenotype Y for the N Y variants ascertained through the association study of Y, and β YX was the vector of the N Y variants' effect sizes on phenotype X. ρ X was defined as Spearman rank correlation between β XX and β XY . Then the rank correlation between β YY and β YX could be expressed as ρ Y . After Fisher's Z-transformation: Ẑ X = arctanh(ρ X ), the sampling distributions of ρ X and ρ Y can be approximated as:
w h e r e N Z X ,
was the density of a normal distribution with mean Z X and variance
. The approximate likelihood for joint probability of the two coefficients can be expressed as 
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As defined by Pickrell et al., there were four models to compare ): The first two models are causal models, while the last two models could be interpreted as non-causal models. Then each model was fitted by maximizing the corresponding approximate likelihood. To compare the fitting effects, the Akaike information criterion (AIC) was calculated for each model and the number of parameters for each model was 1, 1, 0 and 1, respectively. The smallest AIC of causal models (AIC causal ) was chosen from the first two models, and the smallest AIC of non-causal models (AIC non-causal ) was chosen from the last two models. A relative likelihood (r) of the best non-causal model compared to the best causal model was then calculated as r = exp
. As such, r = 0.01 could be interpreted as the relationship between these two phenotypes were 100-fold more likely to be causal rather than non-causal . A less stringent significance threshold of r = 0.05 was also used in this study.
To assess the type I error, we introduced a p value calculated by χ 1 2 test (O'Connor and Price 2017) to give the significance of the difference between Z X and Z Y :
. p values were adjusted using the Benjamini-Hochberg method (Benjamini and Hochberg 1995) to control the false discovery rate (FDR) at level 0.05 if multiple tests were conducted. For inference of putative causal SNPs, Pickrell et al. (2016) split the genome into 1703 approximately independent blocks based on linkage disequilibrium (LD) patterns in the European populations . The 1703 independent blocks were separated by a heuristic approach for choosing segment boundaries. Two sets of SNPs in different blocks were independent if the pairwise r 2 between SNPs in different sets was close to zero . The set of independent putative causal SNPs associated with the phenotype was used to represent N X or N Y . The inferred putative causal SNPs were those with the largest posterior probability of being causal from each block where the regional posterior probability of containing one causal SNP associated with the phenotype was larger than 0.9 .
In our extended method, we also used the 1703 approximately independent blocks and extracted the significant lead SNPs from each block (i.e., the most significant SNPs ranked by their p values) to represent N X and N Y in the causal inference analysis.
Simulation study
To simulate the summary statistics with no LD, we only draw effect sizes of lead SNPs from 1703 independent blocks. The effect sizes were drawn from a multivariate normal distribution with mean of zero, the correlation between phenotype X and Y of ρ and variance of σ X 2 and σ Y 2 for phenotype X and phenotype Y, respectively. To test type I error in the null situations, we let ρ equal to zero, which indicates there is no correlation between the two phenotypes. We assumed that those SNPs with relative large effect sizes in each phenotype were significant SNPs which were further used to give a causal inference. We also varied the number of significant SNPs in each simulation to test whether the type I error rate was inflated when more significant SNPs were used.
To evaluate the power of our extended method, we assumed that phenotype X caused phenotype Y with ρ X at different levels. The effect sizes were drawn from a mixture of multivariate normal distribution for two phenotypes, where a component has ρ at different levels (0.1, 0.3, 0.5, 0.7 and 0.9) and a component has ρ equal to zero. The first component was used to generate the effect sizes of those significant lead SNPs of trait X on both phenotypes. The second component was used to generate the effect sizes of other lead SNPs on either of the two study phenotypes. And this would make sure that the correlation between effect sizes of significant SNPs of phenotype Y on both phenotypes was random and closed to zero. Before the causal inference, we calculated the rank correlation ρ X (the rank correlation between effect sizes of N X significant lead SNPs on phenotype X and effect sizes of N X significant lead SNPs on phenotype Y) to make sure that phenotype X caused phenotype Y with a certain ρ X . The causal inference was conducted only when ρ X was located in an interval (e.g., 0.25-0.35 when ρ was equal to 0.3). We also simulated that there were different numbers (N X and/or N Y ) of significant lead SNPs. In each simulation, we calculated a p value. After 10,000 simulations, the power can then be calculated as the fraction of simulation results with a FDR less than 0.05.
GWAS data
We tested the performance, as an empirical validation, of our extended method using empirical data (GWAS data for 1 3 low-density lipoprotein cholesterol and coronary artery disease), and further applied it to infer the putative causal relationships between metabolites in blood and FN-BMD using GWAS data for blood metabolites and FN-BMD. All the analyses were conducted in European-ancestry individuals.
GWAS data for low-density lipoprotein cholesterol (LDL-c): The Global Lipids Genetics Consortium examined genetic associations with lipid levels (LDL-c, high-density lipoprotein cholesterol, triglycerides and total cholesterol) in 188,577 European-ancestry individuals using genomewide and custom genotyping arrays (Global Lipids Genetics 2013). The summary statistics data for associations with LDL-c were downloaded from http://www.sph.umich .edu/ csg/abeca sis/publi c/lipid s2013 .
GWAS data for coronary artery disease (CAD): The CARDIoGRAM Consortium performed a meta-analysis of 14 GWAS of CAD comprising 22,233 cases and 64,762 controls of European descent (Schunkert et al. 2011 ). The summary statistics data for this study (Schunkert et al. 2011) were downloaded from the CARDIoGRAM consortium (http://www.cardi ogram plusc 4d.org/data-downl oads/).
GWAS data for blood metabolites: A GWAS meta-analysis of two cohorts (TwinsUK and KORA F4) containing 7824 European adult individuals was conducted to identify significant loci associated with metabolite concentrations. A total of 529 metabolites in serum or plasma were detected using liquid phase chromatography and gas chromatography separation coupled with tandem mass spectrometry. After stringent quality controls, a subset of 486 metabolites was included for genetic analysis in both cohorts, including 309 known and 177 unknown metabolites for which chemical identities were not yet determined (Shin et al. 2014 ). TwinsUK cohort was genotyped with Illumina arrays, and KORA F4 cohort was genotyped with Affymetrix GeneChip array 6.0. Subsequently, two cohorts were imputed using reference haplotypes from the HapMap 2 project. The details of data processing were described in previous studies (Illig et al. 2010; Kolz et al. 2009 ). SNPs with minor allele frequency (MAF) > 1% were included in the study. The full results including associations of the 486 metabolites were downloaded from the metabolomics GWAS server (http://metab olomi cs.helmh oltz-muenc hen.de/gwas).
GWAS data for FN-BMD: The GEnetic Factors for OSteoporosis (GEFOS) Consortium conducted a meta-analysis for FN-BMD with 53,236 individuals of European ancestry from the general population (Zheng et al. 2015) . Associations for FN-BMD were derived from whole-genome sequencing, whole-exome sequencing, deep imputation of genotyped samples using a combined UK10 K/1000 Genomes reference panel, and de novo replication genotyping (Zheng et al. 2015) . The summary statistics data were downloaded from the GEFOS website (http://www.gefos .org/). For all the above data, we only included SNPs with minor allele frequency (MAF) > 1% in the causal inference analysis.
Results
To test the performance of our extended causal inference method, we simulated two phenotypes X and Y and assumed different numbers of significant lead SNPs for each phenotype (i.e., N X = N Y = 10, 20, 50 and 100). In each simulation, we performed χ 2 test to assess the significance of the difference between Z X and Z Y and calculated the relative likelihood (r) of the best non-causal model to the best causal model. After 10,000 times of simulations under the non-causal model, we obtained the distribution of p values and r under the null situations ( Fig. 1 and S1 ). The type I errors were very well controlled by our extended method, with no inflation of p values detected when over en lead SNPs were used in the causal inference (Fig. 1b-d) . When a small number (i.e., 10) of genetic variants were used in the causal inference, the rank correlation of these variants' effect sizes on two phenotypes can vary significantly in the null situations. However, this case was not expected if there is a sufficiently large number of genetic variants used in the causal inference. And even when N X = N Y = 10 (Fig. 1a) , we only observed four simulations out of 10,000 that gave a causal conclusion with a FDR < 0.05. It suggested that the thresholds of FDR < 0.05 were useful to control this kind of inflation due to statistical and sampling fluctuation. The distribution of r was also similar to the simulation results of Pickrell's , for which only a small fraction of simulations produced r < 0.01 (Fig. S1 ). In addition, when we used more variants in the analysis, the fraction became smaller (Fig. S1) .
We also used simulations to assess the power of our extended method at different significance levels (Fig. 2) . We assumed that phenotype X caused phenotype Y with ρ X at different levels. In each time, the effect sizes were drawn from a mixture of multivariate normal distribution for two phenotypes, where a component has ρ at different levels (0.1, 0.3, 0.5, 0.7 and 0.9) and a component has ρ equal to zero, and the causal inference was conducted. After 10,000 simulations, the power was calculated as the fraction of simulation result with a FDR < 0.05. As expected, the power for causal inference was enhanced with the increasing number of lead SNPs used as input and the increased true rank correlation (ρ X ) in their effect sizes (Fig. 2) . We also gave the power when it was calculated as the fraction of simulation result with r < 0.01 and 0.05 (Fig. S2) . The results from power simulation (Fig. 2 and S2) suggested that in many situations r < 0.05 was a more conservative threshold than FDR < 0.05.
As LDL-c has been widely accepted as a causal risk factor for CAD (Ference et al. 2012) , we next tested our extended method by inferring the causal relationship between LDL-c (phenotype X) and CAD (phenotype Y) at different significance levels. As expected, the rank correlation ρ X increased along with the increase of the significance levels (Fig. 3a) . When the significance level was more stringent than 1 × 10 −5 , the relative likelihood r was consistently smaller than 0.05 (i.e., log 10 r < -1.30) (Fig. 3b) . Therefore, we selected 1 × 10 −5 as the significance level to be used in our extended method.
Next, we attempted to identify potential causal relationships between blood metabolites and FN-BMD. The association data of 486 metabolites used for causal inference were from a GWAS meta-analysis study which was conducted to identify significant loci associated with metabolite concentrations (Shin et al. 2014) . For all the metabolites tested in the metabolomics GWAS (Shin et al. 2014) , the mean numbers of independent putative causal SNPs were less than 5. Therefore, our extended method was more applicable than Pickrell's method to infer causal relationships between blood metabolites and FN-BMD. Using all the independent lead SNPs with p values < 1 × 10 −5 (3-209 lead SNPs for different metabolites with a mean value of 19), we identified four metabolites (nonadecanoate, 1-stearoylglycerophosphoinositol, 1-palmitoleoyl glycerophosphocholine and leucyl leucine) causally (relative likelihood r < 0.01) influenced FN-BMD (Table 1 and Fig. 4) . With a less stringent threshold of r < 0.05, we identified additional six metabolites (aspartylphenylalanine, ascorbate and four metabolites whose chemical identity were not yet determined) which may have causal effects on FN-BMD (Table 1 and Fig. S3 ). On the other hand, we did not identify any metabolite that may be causally influenced by FN-BMD (data not shown).
Discussion
In this study, we extended Pickrell's causal inference method using the set of independent lead SNPs to replace the set of independent putative causal SNPs and further applied it to infer the putative causal relationship between metabolites in blood and FN-BMD.
Simulations suggested that when the same number of genetic variants was used, our extended method had similar distribution of test statistic under the null model as well as comparable power under the causal model compared to Pickrell's method ). This was not Fig. 1 Distribution of p values in null situations. The effect sizes were drawn from a multivariate normal distribution with mean of zero, the correlation between phenotype X and Y of ρ and variance of σ X 2 and σ Y 2 for phenotype X and phenotype Y, respectively. To test type I error, we set no correlation between the two phenotypes (ρ = 0). In each figure, N X represented the number of independent lead SNPs that influenced phenotype X, and N Y represented the number of independent lead SNPs that influenced phenotype Y. Each distribution was obtained based on 10,000 simulations expected, since the putative causal SNPs used by Pickrell's method were also likely to be the lead SNPs. For example, all the putative causal SNPs identified in the LDL-c data were also the lead SNPs. However, with the stringent criteria (the block posterior probability of containing one causal SNP associated with the phenotype > 0.9) , putative causal SNPs may not be inferred from some significant or suggestive significant blocks. Therefore, the number of independent lead SNPs that can be identified in a GWAS is expected to be larger than the number of independent putative causal SNPs that can be inferred, which leads to higher statistical power of our extended method than Pickrell's method in most simulated situations. If there was no causal relationship between phenotype X and phenotype Y, including more non-significant SNPs gave a smaller ρ X (Fig. 3) , and a smaller ρ X was more unlikely to give a causal conclusion (Fig. 2) . It hence suggested that including more non-significant SNPs, on the other hand, would not cause more false positives. The higher statistical power of our extended method is also demonstrated in the causal inference analysis of metabolites and FN-BMD. Specifically, Pickrell's method failed to identify any significant causal metabolite for FN-BMD (Table 1) , whereas our extended method successfully identified ten metabolites that may causally influence FN-BMD.
Several studies have attempted to improve Mendelian randomization. For example, the generalized summary databased Mendelian randomization analysis (GSMR) allows using the correlated genetic variants (Zhu et al. 2017) . The Mendelian Randomization Pleiotropy RESidual Sum and Outlier (MR-PRESSO) test can correct for distortion in the causal estimate in most cases by the removal of offending instrumental variables that exhibit pleiotropy (Verbanck et al. 2017) . The latent causal variable (LCV) model can quantify the degree of partial genetic causality (O'Connor and Price 2017). The causal inference test (CIT) would be more likely to give an unbiased result even when the measurement error existed (Hemani et al. 2017) . Compared with these methods, our extended method allowed using more genetic variants while maintaining well-controlled type I error rate. Previous studies (Brion et al. 2013; Freeman et al. 2013) have shown that when the genetic variants that are used to estimate the causal effects collectively explain a larger proportions of the variance in the causal phenotype (the exposure in Mendelian randomization studies), this will lead to more precise estimates of causal effects and thus increase the power for detecting the causal relationships. And if a small number of genetic variants have pleiotropic effects on the phenotypes, it would cause little change of ρ XY Fig. 2 Power to detect a causal relationship. We simulated data under a model that phenotype X caused phenotype Y with rank correlation (ρ X ) at different levels. The effect sizes were drawn from a mixture of multivariate normal distribution, where a component has ρ at different levels (0.1, 0.3, 0.5, 0.7 and 0.9) and a component has ρ equal to zero. In each simulation, we assumed the number of independent lead SNPs was 10, 20, 50 or 100, and calculated the fraction of the results with FDR < 0.05 Fig. 3 Inferring the causal relationship between LDL-c (phenotype X) and CAD (phenotype Y) at different significance levels. In each significance level, lead SNPs, whose p values were less than the significant level, were extracted from two traits to estimate the rank correlation ρ X (a) and relative likelihood (b) (the rank correlation between the effect sizes of significant phenotype X SNPs on phenotype X and phenotype Y), so the results would be robust (data not shown).
Metabolomics is an emerging "omics" science that can identify low molecular weight metabolites from tissues, cells or biological fluids (Dettmer and Hammock 2007; Wilson et al. 2005) . Metabolites in blood play important roles in numerous biological pathways and reflect the dynamic biological changes closest to the phenotype (Kettunen et al. 2012; Smilde et al. 2010) . Therefore, identifying the causal relationships between metabolites and phenotypes will be helpful in fully understanding the mechanism of diseases development. Osteoporosis is a major skeletal disorder characterized by low BMD and an increased susceptibility to fractures (Cummings and Melton 2002) . Hip was one of the most prevalent osteoporotic fracture sites, and FN-BMD has the highest predictive value for hip fracture (Cartwright 2009) . In this study, we identified ten blood metabolites that may causally influence FN-BMD. For example, genetic variants that influenced ascorbate, which was also known as vitamin C, had correlated effect on FN-BMD (Table 1 and Fig. S3D ). The positive correlation coefficient (ρ X = 0.66) can be roughly interpreted that the increased concentration of ascorbate caused the increased FN-BMD. This was consistent with previous finding that high plasma levels or dietary intake of antioxidants is associated with increased BMD (Maggio et al. 2003; Sugiura et al. 2011 ). In addition, ascorbate is a cofactor in collagen formation and hydroxylation of lysine and proline (Peterkofsky et al. 1994) , which is important for bone maintenance (Bonucci 2012) . Another example was aspartylphenylalanine, which is a dipeptide composed of aspartate and phenylalanine. Aspartylphenylalanine can be major decomposition products of aspartame degraded from aspartame via intramolecular cyclization and liberation of methanol (Lin 2000) . Aspartame, given orally, improves the bone cortical density and muscle mass in mouse (Manion et al. 2011) . This was consistent with our finding (Fig. S3A ) that aspartylphenylalanine probably helped the increase of FN-BMD (ρ X = 0.86). However, a little was known about the functions of the top four metabolites (Table 1) and their roles on bone metabolism warrants further functional analysis. On the other hand, our analysis did not detect several metabolites that were previously known to be causally associated with BMD, such as vitamin K (Palermo et al. 2017) . This is mainly because that some of these metabolites (e.g., vitamin K) were not included in the metabolomics GWAS dataset (Shin et al. 2014 ).
Conclusions
Our extended method was applicable to give a causal estimation between phenotypes even when there were few independent putative causal SNPs identified. We identified a list of metabolites that may causally influence FN-BMD, which provided novel insights in the mechanism of osteoporosis development.
